Cardinal Health to pay $490M for Enturia disinfection products
Cardinal Health, a provider of products and services that improve the safety and productivity of health care, has signed a definitive agreement to acquire the assets of Enturia for $490 million.
The cash transaction includes Enturia’s line of infection prevention products sold under the ChloraPrep brand name and is expected to close within 60 days, subject to customary regulatory approvals and other conditions, according to the Dublin, Ohio-based Cardinal.
ChloraPrep brand products are used in hospitals and surgery centers to disinfect the skin before surgical and vascular procedures to help prevent blood stream and surgical site infections.
Cardinal said the acquisition of the Kansas, Texas-based Enturia will complement its infection prevention offerings by adding a differentiated product line to its medical products and technologies segment.
Cardinal said it plans to accelerate sales of ChloraPrep products to both hospital and alternate-care customers through its U.S. and international sales networks.
The company said the acquisition is expected to be slightly dilutive to Cardinal’s earnings for the remainder of fiscal year 2008 and accretive each year thereafter. The company’s outlook for non-GAAP diluted earnings per share from continuing operations for fiscal 2008, including the impact of the acquisition, remains unchanged.
Enturia currently has about 600 employees in Kansas, Texas and the United Kingdom.
The cash transaction includes Enturia’s line of infection prevention products sold under the ChloraPrep brand name and is expected to close within 60 days, subject to customary regulatory approvals and other conditions, according to the Dublin, Ohio-based Cardinal.
ChloraPrep brand products are used in hospitals and surgery centers to disinfect the skin before surgical and vascular procedures to help prevent blood stream and surgical site infections.
Cardinal said the acquisition of the Kansas, Texas-based Enturia will complement its infection prevention offerings by adding a differentiated product line to its medical products and technologies segment.
Cardinal said it plans to accelerate sales of ChloraPrep products to both hospital and alternate-care customers through its U.S. and international sales networks.
The company said the acquisition is expected to be slightly dilutive to Cardinal’s earnings for the remainder of fiscal year 2008 and accretive each year thereafter. The company’s outlook for non-GAAP diluted earnings per share from continuing operations for fiscal 2008, including the impact of the acquisition, remains unchanged.
Enturia currently has about 600 employees in Kansas, Texas and the United Kingdom.